Atrium Therapeutics, Inc.

What they do

Atrium uses a targeted RNA delivery platform that combines monoclonal antibody tissue selectivity with oligonucleotide precision to reach the heart. Its two lead wholly owned candidates are ATR 1072, an siRNA targeting PRKAG2 for PRKAG2 syndrome, and ATR 1086, an siRNA targeting phospholamban for PLN cardiomyopathy. It also has two undisclosed research programs against rare cardiology targets. Revenue today comes from a research collaboration and license agreement with Bristol Myers Squibb, not from product sales.

Revenue drivers

• Bristol Myers Squibb collaboration — The company earns collaboration revenue for R&D services under a global cardiovascular research collaboration and license agreement; Q2 2026 collaboration revenue was $3.0 million.
• BMS milestone payments — Atrium earned a second milestone in August 2026 triggering a $15 million payment, to be recorded in Q3 2026 financials.

Recent performance

Q2 2026 collaboration revenue was $3.0 million, down from $19.6 million in Q1 2026, a quarter that appears to have included a larger collaboration item. R&D expenses were $15.3 million and G&A was $10.3 million in Q2 2026. The company reported $263.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, versus $72.3 million of cash and equivalents on the balance sheet. Total assets were $280.5 million and total liabilities $65.9 million at June 30, 2026. No product revenue has been recognized; Atrium remains preclinical/clinical-stage on its own pipeline.

Strategy

Atrium is prioritizing clinical execution on ATR 1072, its lead PRKAG2 syndrome candidate, following FDA IND clearance and a Health Canada No Objection Letter. It launched the Corventis Phase 1/2 trial and expects to enroll the first participant by the end of 2026. It plans to file an IND for ATR 1086 in 2027, with IND-enabling studies starting in 2026. The company also expects to select its next development candidate in 2027 from two undisclosed rare cardiomyopathy programs. It funds this through its BMS collaboration and existing cash, which management says is sufficient through mid-2028.

Risks

• Clinical-stage dependence — Atrium has no approved products and its prospects depend on ATR 1072 and ATR 1086 succeeding in trials that have not yet dosed a first patient.
• Concentrated collaboration revenue — Revenue comes from the BMS collaboration, including milestone payments such as the $15 million earned in August 2026, so timing and achievement of milestones drive reported results.
• Early-stage pipeline — Corventis is a Phase 1/2 open-label trial of approximately 37 participants, and initial proof-of-concept data are not expected until the second half of 2027.
• Limited standalone operating history — Atrium became an independent public company through a spin-off from Avidity Biosciences, so historical results may not be indicative of future performance as a standalone entity.

Outlook

Management expects the first participant in the Corventis Phase 1/2 trial of ATR 1072 to be enrolled by the end of 2026, with initial proof-of-concept data in the second half of 2027. It expects to file an IND for ATR 1086 in 2027 and to select a next development candidate in 2027. Atrium states its current cash resources, including the August 2026 BMS milestone, are sufficient to fund planned operations through mid-2028.